Table 2.
IFNγ-mediated cell cycle effects in melanoma cells.
| Cell line | Driver mutation | Sub-G1 phase |
G1 phase |
S phase |
G2 phase |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| − | + | − | + | − | + | – | + | IFNγ effect | ||
| A2058 | BRAFV600E | 0.6 | 1.3 | 68.2 | 63.3 | 19.2 | 26.7 | 12.7 | 10.1 | ↑ S phase |
| SKMel28 | BRAFV600E | 1.7 | 3.8 | 72.4 | 73.5 | 19.6 | 13.3 | 8.0 | 13.3 | ↓ S phase |
| C060M1 | BRAFV600E | 1.1 | 2.4 | 72.1 | 68.2 | 12.1 | 11.9 | 16.1 | 19.9 | |
| SCC14-0257 | BRAFV600K | 1.6 | 5.3 | 63.4 | 50.5 | 20.0 | 26.1 | 16.6 | 23.4 | ↑ S phase |
| MM418 | BRAFV600E | 0.9 | 9.5 | 61.8 | 54.9 | 24.8 | 32.4 | 13.4 | 12.7 | ↑ S phase |
| NM16 | BRAFV600E | 0.8 | 4.1 | 65.6 | 70.1 | 26.3 | 26.8 | 8.1 | 3.1 | |
| NM182 | BRAFV600E | 2.5 | 4.1 | 60.8 | 56.3 | 28.4 | 34.8 | 10.8 | 8.9 | |
| MM200 | BRAFV600E | 1.1 | 17.1 | 69.9 | 62.2 | 19.9 | 31.1 | 10.2 | 6.7 | ↑ sub-G1, ↑ S phase |
| NM39 | BRAFV600E | 0.7 | 2.3 | 85.2 | 86.4 | 9.7 | 9.8 | 5.0 | 3.8 | |
| HT144 | BRAFV600E | 1.6 | 12.9 | 65.4 | 61.7 | 24.3 | 24.4 | 10.4 | 13.9 | ↑ sub-G1 |
| C016M | BRAFV600E | 4.0 | 6.8 | 73.2 | 65.4 | 19.8 | 22.9 | 7.0 | 11.7 | |
| MelRm | NRASQ61R | 0.7 | 4.1 | 62.9 | 64.9 | 26.8 | 24.2 | 10.3 | 10.8 | |
| NM47 | NRASQ61R | 0.4 | 6.5 | 63.0 | 65.3 | 25.8 | 24.3 | 11.2 | 10.4 | |
| NM177 | NRASQ61R | 2.6 | 2.9 | 67.6 | 59.5 | 23.3 | 28.4 | 9.0 | 12.2 | |
| NM179 | NRASQ61K | 1.7 | 6.7 | 60.1 | 52.5 | 24.8 | 32.9 | 15.0 | 14.7 | ↑ S phase |
| ME4405 | NRASQ61R | 0.3 | 0.7 | 59.7 | 63.6 | 28.2 | 26.1 | 12.1 | 10.2 | |
| MelAT | NRASQ61R | 0.5 | 0.8 | 58.2 | 68.0 | 29.7 | 22.7 | 12.2 | 9.3 | |
| D11M2 | NRASQ61L | 7.8 | 8.7 | 41.7 | 39.7 | 33.4 | 28.2 | 24.9 | 32.2 | |
| C002M | NRASQ61K | 1.4 | 2.5 | 73.3 | 65.5 | 17.7 | 27.0 | 8.9 | 7.5 | ↑ S phase |
| C013M | NRASQ61L | 19.0 | 35.5 | 57.1 | 54.2 | 26.4 | 23.8 | 16.6 | 21.9 | ↑ sub-G1 |
| D38M2 | NRASQ61R | 0.7 | 1.3 | 65.1 | 59.9 | 18.2 | 21.3 | 16.7 | 18.9 | |
| D22M1 | BRAF/NRASWT | 1.2 | 1.2 | 52.7 | 50.9 | 37.9 | 39.5 | 9.4 | 9.5 | |
| MeWo | BRAF/NRASWT | 1.1 | 1.7 | 49.2 | 52.9 | 25.5 | 24.1 | 25.4 | 22.9 | |
| D24M | BRAF/NRASWT | nd | nd | nd | nd | nd | nd | nd | nd | |
| C022M1 | BRAF/NRASWT | 1.4 | 4.1 | 80.2 | 68.3 | 11.5 | 17.6 | 8.2 | 14.1 | ↑ S phase |
| C084M | BRAF/NRASWT | 0.6 | 1.2 | 37.0 | 37.8 | 22.5 | 16.4 | 40.6 | 45.8 | |
| C086M | BRAF/NRASWT | 4.7 | 13.4 | 50.4 | 48.8 | 34.0 | 25.9 | 15.6 | 25.3 | |
| D35M1 | BRAF/NRASWT | 0.3 | 1.3 | 71.9 | 72.8 | 20.7 | 23.5 | 7.5 | 3.7 | |
| C025M1 | BRAF/NRASWT | 1.2 | 1.4 | 75.5 | 78.0 | 17.7 | 16.1 | 6.8 | 5.6 | |
| SMU15-0217 | BRAF/NRASWT | 0.6 | 1.4 | 69.5 | 67.5 | 22.2 | 21.0 | 8.3 | 11.5 | |
| A04-GEH | BRAF/NRASWT | 1.0 | 7.7 | 60.0 | 56.9 | 25.7 | 24.7 | 14.3 | 18.4 | |
| 92.1 | GNAQQ209L | 0.7 | 8.3 | 60.6 | 87.0 | 31.6 | 10.3 | 7.9 | 2.7 | ↓ S phase |
| MEL202 | GNAQQ209L, R210K | 0.4 | 5.2 | 57.5 | 72.8 | 26.8 | 17.3 | 15.7 | 9.9 | ↓ S phase |
| MEL270 | GNAQQ209P | 0.8 | 1.4 | 68.7 | 69.9 | 21.8 | 20.8 | 9.5 | 9.3 | |
| MP38 | GNAQQ209P | 0.6 | 2.2 | 72.7 | 88.4 | 12.0 | 4.2 | 15.4 | 7.4 | ↓ S phase |
| OMM1 | GNA11Q209L | 1.4 | 1.4 | 53.4 | 52.3 | 35.8 | 36.4 | 10.9 | 11.4 | |
| MP41 | GNA11Q209L | 1.2 | 4.1 | 60.7 | 84.0 | 28.3 | 12.1 | 11.0 | 3.9 | ↓ S phase |
| MP46 | GNAQQ209L | 1.2 | 1.8 | 28.7 | 29.1 | 10.4 | 10.1 | 57.3 | 61.4 | |
| MM28 | GNA11Q209L | 0.7 | 1.2 | 85.6 | 92.4 | 7.1 | 3.4 | 7.3 | 4.3 | ↓ S phase |
Percentage of cells in the indicated cell cycle phase is shown. Data are the average of at least three independent experiments. S phase data indicate either 30% increase (↑) or decrease (↓) in the proportion of cells undergoing DNA replication, calculated as [(S phaseIFNγ − S phaseBSA)/S phaseBSA].
↑ sub G1 indicates a greater than 10% increase in sub G1 cells in response to IFNγ treatment (sub G1IFNγ − sub G1BSA).
Cells showing no IFNγ-mediated PD-L1 induction are shown in bold.
−, no IFNγ treatment; +, treated for 72 h with 1,000 U/ml IFNγ; nd, not determined; IFNγ, interferon-γ; BSA, bovine serum albumin.